D-ERYTHRO-SPHINGOSINE

CAS No. 123-78-4

D-ERYTHRO-SPHINGOSINE( Erythrosphingosine | erythro-C18-Sphingosine | trans-4-Sphingenine )

Catalog No. M20525 CAS No. 123-78-4

D-erythro-Sphingosine is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 35 In Stock
25MG 58 In Stock
50MG 102 In Stock
100MG 155 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    D-ERYTHRO-SPHINGOSINE
  • Note
    Research use only, not for human use.
  • Brief Description
    D-erythro-Sphingosine is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.
  • Description
    D-erythro-Sphingosine is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Erythrosphingosine | erythro-C18-Sphingosine | trans-4-Sphingenine
  • Pathway
    Angiogenesis
  • Target
    PKC
  • Recptor
    PKC|PP2A|Human Endogenous Metabolite
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    123-78-4
  • Formula Weight
    299.49
  • Molecular Formula
    C18H37NO2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (834.75 mM)
  • SMILES
    CCCCCCCCCCCCC\C=C\C(O)C(N)CO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Khan W A Dobrowsky R El T S et al. Protein kinase C and platelet inhibition by D-erythro-sphingosine: comparison with NN-dimethylsphingosine and commercial preparation.[J]. Biochemical & Biophysical Research Communications 1990 172(2):683-691.
molnova catalog
related products
  • PKC-IN-7

    PKC-IN-7 is a potent, selective, reversible, ATP-competitive PKCα/β inhibitor with IC50 of 4.7/3.3 nM.

  • DCPLA-ME

    DCPLA-ME is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.

  • Roy-Bz

    Roy-Bz is the?first?small-molecule?PKCδ-selective activator with EC50 of 58.5 nM, binds to the PKCδ-C1-domain.